Seoul, South Korea – Daewoong Pharmaceutical's domestically developed diabetes drug, Envlo (inavogliflozin), has shown promising results in treating patients with diabetes and kidney disease, according to a recent study conducted at the University of Leicester in the UK.
The findings were presented at the International Congress of Diabetes (ICDM 2024) by a panel of experts, including Professor Melanie Davies, a renowned diabetes specialist at the University of Leicester.
Davies, a former president of the European Association for the Study of Diabetes and the American Diabetes Association, presented data from three Phase 3 clinical trials demonstrating Envlo's efficacy in lowering blood sugar levels in patients with type 2 diabetes.
"Envlo has shown superior blood glucose lowering effects compared to dapagliflozin in clinical trials," said Davies. "It has the potential to be a valuable treatment option for a wide range of patients."
Davies highlighted that Envlo was particularly effective in patients with mild kidney impairment, outperforming the existing SGLT-2 inhibitor dapagliflozin. She suggested that further research could explore the efficacy of Envlo in patients with moderate to severe kidney impairment.
Kim Shin-gon, a professor at Korea University College of Medicine, also presented at the conference, discussing the past, present, and future of SGLT-2 inhibitors. He highlighted the ongoing ENVELOP study, which is evaluating the effects of Envlo on heart and kidney outcomes.
"SGLT-2 inhibitors have been shown to be effective in treating heart failure and kidney disease, regardless of whether the patient has diabetes," Kim said. "Further studies are needed to evaluate the benefits of these drugs in a wider range of patients."
Envlo, a first-in-class SGLT-2 inhibitor, has demonstrated superior efficacy at a significantly lower dose compared to existing SGLT-2 inhibitors. It has shown promising results in reducing blood sugar levels, weight, and blood pressure in patients with type 2 diabetes.
"We are delighted that the efficacy and safety of Envlo, our domestically developed diabetes drug, have been recognized at the ICDM," said Lee Chang-jae, CEO of Daewoong Pharmaceutical. "We believe that Envlo has the potential to become a new treatment option for patients with diabetes and other related conditions."
[Copyright (c) Global Economic Times. All Rights Reserved.]
